Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

e III endpoint is substantially smaller than the 33% increase seen in Phase II.
  • No toxicity issues have been identified.
  • No safety issues have been identified.
  • Clear unmet medical need.
  • FDA granted Multikine Orphan Drug status in the USA.

  • Our clinical success would be huge since Multikine would be on course to become the recommended first-line treatment for head and neck cancer. From there, we could hopefully prove that Multikine is likely to work against other solid tumors as well.

    Our ultimate goal in development is to provide patients and physicians with a new and better way of fighting cancer. We believe that the key to doing so lies in our immune system. Dendreon's prostate cancer vaccine recently established that this is possible. Their success is even more impressive because they focused on late-stage cancer patients. We believe that Multikine should have an even greater chance of success because we focus on patients not yet treated for their cancer. Their immune system is still intact, except in the area of the tumor, and their lymphatics have not yet been cut, meaning that they can still deliver immune cells from the local lymph nodes to the tumor.

    From here on there is only one thing to do. We will launch the Phase III study as quickly as possible. Success would be phenomenal, and we anticipate that it should enable rapid approval around the world.

    We thank you for your continued support.

    Sincerely,

    Geert Kersten

    Chief Executive Officer

    When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.
    '/>"/>

    SOURCE CEL-SCI Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. CEL-SCI to Present at the Noble Financial Conference
    2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
    3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
    4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    5. CEL-SCI Takes Delivery of New Manufacturing Facility
    6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
    7. CEL-SCI Corporation Releases Letter to Shareholders
    8. CEL-SCI Corporation Announces 2008 Financial Results
    9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
    10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
    11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/17/2015)... Reed Technology and Information Services ... management, preparation, and submission to the U.S. Food and ... new Lot Distribution Report (LDR) service for manufacturers of ... with the FDA’s new rule on electronic submission of ... the volume and timing of particular biologics introduced to ...
    (Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the investment ... announced the hiring of William Tanner as ... Mr. Tanner will start work at Guggenheim in ... office. "Bill brings a wealth ... to our experienced and highly acclaimed healthcare team," said ...
    (Date:4/17/2015)... 2015 LC Sciences LLC, a ... today that it is seeking beta testers for ... PCR based targeted sequencing technology. The system offers ... enables accurate detection of rare variants. It utilizes ... The company will collaborate with beta testers to ...
    (Date:4/16/2015)... KYOTO and OSAKA, Japan ... iPS Cell Research Application (CiRA) of Kyoto University ... that they will work together to develop clinical ... such as heart failure, diabetes mellitus, neurological disorders ... iPS Cell Applications" (T-CiRA) is designed to expedite ...
    Breaking Biology Technology:Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
    ... tools and find the organisms to break down the ... the key step toward fermentation of those sugars ... and economically efficient before cellulosic biofuels can compete with ... any exploration of systems that involve largely unknown processes, ...
    ... Inc. (Nasdaq: ONTY ) will conduct a conference call to discuss its ... 4:30 p.m. Eastern time ( 1:30 p.m. Pacific time ). , ... To participate in the call by telephone, ... addition, the call will be webcast live and can be accessed on the ...
    ... CHICAGO , July 26 Advanced ... Board: ADLS), a biopharmaceutical company engaged in the discovery, ... areas of infection, oncology and respiratory diseases, today announced ... and option agreement with The University of British ...
    Cached Biology Technology:New hydrolysis model promising tool in cellulosic biofuel studies 2New hydrolysis model promising tool in cellulosic biofuel studies 3Advanced Life Sciences Expands Antibiotic Pipeline 2Advanced Life Sciences Expands Antibiotic Pipeline 3Advanced Life Sciences Expands Antibiotic Pipeline 4
    (Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
    (Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
    (Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
    Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
    ... SPRING HARBOR, N.Y. (Jan. 11, 2011) -- The ... a decade ago, has revolutionized biological research. But ... and linking basic biological processes to genomic information can ... new resource that provides easy access to information about ...
    ... One of the challenges of gene therapy - a set ... or RNA) - is to assure that this material arrives ... substantial amount along the way and without producing any undesired ... use of different types of vectors, molecules capable of transporting ...
    ... microscope, a coronavirus may resemble a spiny sea urchin or ... takes its name). Previously recognized as the second leading ... important diseases in many domesticated animals, a new disease form ... when the SARS coronavirus (CoV) surfaced in Asia. The ...
    Cached Biology News:New user-friendly resource connects human genes to biological functions 2Nanodisk gene therapy 2New research aims to shut down viral assembly line 2New research aims to shut down viral assembly line 3New research aims to shut down viral assembly line 4New research aims to shut down viral assembly line 5
    ... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
    Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
    Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
    KOR-1 (C-20)...
    Biology Products: